Multiple Myeloma Clinical Trial
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Summary
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
18 years and older'
diagnosed with active R/RMM, who have failed 2 lines of treatment
have measurable disease
Exclusion Criteria:
- Patients with active plasma cell leukemia
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There are 3 Locations for this study
See Locations Near You
Louisiana State University Health Science Center at Shreveport
Shreveport Louisiana, 71103, United States More Info
Shreveport Louisiana, 71103, United States More Info
Tamna Wangjam, M.D.
Principal Investigator
Principal Investigator
Center for Cancer and Blood Disorders
Bethesda Maryland, 20817, United States More Info
Bethesda Maryland, 20817, United States More Info
Investigator
Contact
Contact
Saglik Bilimleri Universitesi
Ankara Anatolia, 06200, Turkey More Info
Ankara Anatolia, 06200, Turkey More Info
Fevzi Altuntas, MD
Principal Investigator
Principal Investigator
How clear is this clinincal trial information?